Digital repository of Slovenian research organisations

Search the repository
A+ | A- | Help | SLO | ENG

Query: search in
search in
search in
search in

Options:
  Reset


Query: "author" (Perhavec Andraž) .

1 - 10 / 27
First pagePrevious page123Next pageLast page
1.
Sledenje bolnic z rakom dojk
Andraž Perhavec, 2023, published professional conference contribution

Keywords: rak dojk, rehabilitacija, celostno zdravljenje
Published in DiRROS: 08.01.2024; Views: 146; Downloads: 31
.pdf Full text (190,63 KB)

2.
Kirurgija pazduhe
Andraž Perhavec, 2023, published professional conference contribution

Keywords: rak dojk, kirurško zdravljenje, kirurgija
Published in DiRROS: 08.01.2024; Views: 142; Downloads: 31
.pdf Full text (192,21 KB)

3.
Šola raka dojk : [strokovno srečanje]
2023, not set

Keywords: epidemiologija, presejanje, genetsko svetovanje, rehabilitacija, rekonstrukcija, zborniki
Published in DiRROS: 11.12.2023; Views: 220; Downloads: 63
.pdf Full text (14,08 MB)

4.
5.
Napovedna vrednost ultrazvočne ocene pazdušnih bezgavk po neoadjuvantem sistemskem zdravljenju pri bolnicah z rakom dojk
Nina Pišlar, Janez Žgajnar, Simona Borštnar, Andraž Perhavec, 2022, published professional conference contribution abstract

Keywords: onkologija, rak dojke, pazdušne bezgavke
Published in DiRROS: 09.02.2023; Views: 364; Downloads: 95
.pdf Full text (45,39 KB)

6.
7.
Programske smernice DORA
Mateja Kurir-Borovčić, Amela Duratović Konjević, Katja Jarm, Katarina Nagode, Maksimiljan Kadivec, Zvonka Kastelic, Veronika Kutnar, Andraž Perhavec, Barbara Skubic-Vengušt, Stanka Sabo, Špela Sitar, Stančka Suljić, Cveto Šval, Anastazija Šelih, Vesna Škrbec, Miloš Vrhovec, Sonja Tomšič, Katarina Torkar, Urban Zdešar, Kristijana Hertl, 2022, professional monograph

Abstract: Državni presejalni program za raka dojk DORA (v nadaljevanju: program DORA) vabi ženske med 50. in 69. letom vsaki dve leti na presejanje z mamografijo, katerega cilj je zmanjšati umrljivost za rakom dojk v ciljni populaciji za 25 do 30 odstotkov. Nosilec programa DORA je Onkološki inštitut Ljubljana. Presejalno mamografijo opravlja 16 javnih zdravstvenih zavodov po Sloveniji na 20 digitalnih mamografih s kadri, ki so za svoje delo posebej usposobljeni. Dodatno diagnostiko in zdravljenje raka dojk, odkritega v presejanju, izvajata presejalno-diagnostična centra na Onkološkem inštitutu Ljubljana in v Univerzitetnem kliničnem centru Maribor. Te programske smernice opredeljujejo presejalno politiko programa DORA, postopek obravnave žensk, organizacijo in dejavnosti programa DORA. Delijo se na upravljalske, zdravstvene in druge storitve. Sestavni del teh programskih smernic je tudi določitev strokovnega nadzora, ki se opravlja v presejalnem programu, ter podrobnejši Standardni operativni postopki (SOP) delovanja programa DORA. Sestavni del tega dokumenta so tudi Protokoli in priloge.
Keywords: rak dojke, programske smernice, presejalni programi, svetovanje
Published in DiRROS: 08.12.2022; Views: 557; Downloads: 237
.pdf Full text (328,03 KB)
This document has many files! More...

8.
Dopolnitev in uskladitev smernic : enotno sledenje
Andraž Perhavec, 2022, published scientific conference contribution

Keywords: sarkomi, rak maternice, ginekološka onkologija, sarkomi maternice
Published in DiRROS: 16.11.2022; Views: 442; Downloads: 174
.pdf Full text (215,19 KB)
This document has many files! More...

9.
Prikaz kliničnih primerov – OI Ljubljana
Nina Pišlar, Andraž Perhavec, Marko Novak, 2022, published scientific conference contribution

Keywords: sarkomi, rak maternice, ginekološka onkologija, bolniki
Published in DiRROS: 16.11.2022; Views: 565; Downloads: 201
.pdf Full text (266,98 KB)
This document has many files! More...

10.
Trends and timing of risk-reducing mastectomy uptake in unaffected BRCA1 and BRCA2 carriers in Slovenia
Taja Ložar, Janez Žgajnar, Andraž Perhavec, Ana Blatnik, Srdjan Novaković, Mateja Krajc, 2021, original scientific article

Abstract: Objectives. Risk-reducing mastectomy (RRM) is one of key prevention strategies in female carriers of germline BRCA pathogenic/likely pathogenic variants (PV/LPV). We retrospectively investigated the rate, timing and longitudinal trends of bilateral RRM uptake and the incidence and types of cancers among unaffected BRCA carriers who underwent genetic counseling at the Institute of Oncology Ljubljana in Slovenia. Materials and Methods. Female BRCA carriers without personal history of cancer were included in the study. Clinical data on PV/LPV type, date of RRM, type of reconstructive procedure, occult carcinoma and histopathology results was collected and analyzed. Results. Of the 346 unaffected BRCA carriers (median age 43 years, 70% BRCA1, 30% BRCA2, median follow-up 46 months) who underwent genetic testing between October 1999 and December 2019, 25.1% had a RRM (range 35-50 years, median age at surgery 38 years). A significant difference in time to prophylactic surgery between women undergoing RRM only vs. women undergoing RRM combined with risk-reducing salpingo-oophorectomy was observed (22.6 vs 8.7 months, p=0.0009). We observed an upward trend in the annual uptake in line with the previously observed Angelina Jolie effect. In 5.7% of cases, occult breast cancer was detected. No women developed breast cancer after RRM. Women who did not opt for surgical prevention developed BRCA1/2-related cancers (9.3%). Conclusion. The uptake of RRM among unaffected BRCA carriers is 25.1% and is similar to our neighboring countries. No women developed breast cancer after RRM while women who did not opt for surgical prevention developed BRCA1/2 related cancers in 9.3% of cases. The reported data may provide meaningful aid for carriers when deciding on an optimal prevention strategy.
Keywords: risk-reducing mastectomy, breast cancer, BRCA
Published in DiRROS: 21.09.2022; Views: 410; Downloads: 139
.pdf Full text (593,94 KB)

Search done in 0.35 sec.
Back to top